D
David de Bono
Researcher at Cleveland Clinic
Publications - 6
Citations - 3828
David de Bono is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Myocardial infarction & Streptokinase. The author has an hindex of 5, co-authored 6 publications receiving 3665 citations.
Papers
More filters
Journal ArticleDOI
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
Maarten L. Simoons,Eric J. Topol,Robert M. Califf,Frans Van de Werf,Paul W. Armstrong,Philip Edmund Aylward,G.I. Barbash,Eric R. Bates,A. Betriu,James Chesebro,J Col,David de Bono,JM Gore,Alan Guerci,John R. Hampton +14 more
TL;DR: The findings of this large-scale trial indicate that accelerated t-PA given with intravenous heparin provides a survival benefit over previous standard thrombolytic regimens.
Journal ArticleDOI
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
Marc Verstraete,A. E. R. Arnold,Ronald W. Brower,Desire Collen,David de Bono,Chris de Zwaan,Rainer Erbel,W.Stuart Hillis,R.John Lennane,Jacobus Lubsen,Detlef G. Mathey,Douglas S. Reid,Wolfgang Rutsch,M. Schartl,Joachim Schofer,Patrick W. Serruys,Maarten L. Simoons,Rainer Uebis,Alec Vahanian,Freek W.A. Verheugt,Rainer von Essen +20 more
TL;DR: An intravenous infusion of 40 mg of recombinant tissue-type plasminogen activator (rt-PA) was given intravenously over 90 minutes to 123 patients with acute myocardial infarction of less than 4 hours' duration, and no difference in late reocclusion rates between the 2 treatment groups was observed.
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction.
Alfred Arnold,Maarten L. Simoons,David de Bono,Jan Tijssen,Patrick Serruys,Marc Verstraete,Jacob Lubsen,Frans Van de Werf +7 more
TL;DR: In this article, the authors conducted two randomized trials in patients with suspected myocardial infarction to assess the effect of 100 mg single-chain recombinant tissue-type plasminogen activator (rt-PA, alteplase) on enzymatic infarct size, left ventricular function, morbidity and mortality relative to placebo.
Thrombolysis with rt-PA in acute myocardial infarction: no additional benefit of immediate PTCA
Maarten L. Simoons,Amadeo Betriu,M. Bokslag,David de Bono,Ronald W. Brower,J Col,F. C. Dougherty,R. Von Essen,Heinz Lambertz,Jacob Lubsen,B. Meier,Michel Pl,Philippe Raynaud,Wolfgang Rutsch,G.A. Sanz,W. Schmidt,Patrick Serruys,C. Thery,Rainer Uebis,A Vahanian,George M. Willems,David A. Wood,Marc Verstraete,Alfred Arnold,Frans Van de Werf +24 more
TL;DR: There seems to be no need for immediate angiography and PTCA in patients with acute myocardial infarction treated with rTPA, with a lower incidence of recurrent ischaemia, bleeding complications, hypotension, and ventricular fibrillation after non-invasive therapy.